to be inoperable due to significant comorbidities. 1 Secondly, BAV was used as a bridge to surgical aortic valve replacement (SAVR) in patients who were high-risk or hemodynamically unstable preoperatively. 2 Data on immediate hemodynamic outcomes after BAV demonstrate an approximately 50% reduction in peak aortic valve gradient with an increase in aortic valve area ranging from 0.3 to 0.5 cm 2 . [3] [4] [5] [6] However, rates of valvular restenosis by 6 months were greater than 70%. 4, 5 Because of these suboptimal outcomes with BAV, the ACC/AHA guidelines only recommend BAV as a bridge to SAVR or TAVR in patients with severe, symptomatic AS (Class IIb, level of evidence C). 7 With the development of TAVR as a treatment option for inoperable and high-risk patients for aortic valve replacement, 8, 9 the use of BAV has increased. 10 The increase in BAV in the TAVR era has occurred as a "bridge-to-decision" in patients not felt to be definitive TAVR candidates at first evaluation, most commonly secondary to comorbidities or frailty. Frailty evaluation has increased in importance with the demonstration of increased mortality and major morbidity post cardiac surgery with increasing frailty. 11, 12 Additionally, early data have also demonstrated increased 1-year mortality post TAVR in more frail patients. 13 The most common single way to define frailty in the cardiovascular realm has been with evaluation of gait speed (GS) by a standardized 5 m walk test. 14 There are limited data on the effect of BAV on frailty measures in patients being evaluated for TAVR. Additionally, clinical status as measured by New York Heart Association (NYHA) congestive heart failure (CHF) functional class can also be used to define improvement post BAV. This study aimed to evaluate whether BAV can be used as a rehabilitative tool by comparing frailty testing and NYHA functional class before and after BAV in patients at high risk for AVR.
| MATERIALS AND METHODS
A retrospective analysis of 117 consecutive patients with severe, symptomatic AS who were evaluated by a multidisciplinary Heart
Team and felt to be high-risk or inoperable surgical candidates and not All patients underwent frailty testing as part of their evaluation.
The first component of frailty tested was gait speed. Qualified patients were instructed to walk 5 m (16.4 feet) in a designated, well-lit, open hallway at a comfortable pace. 15 The timer was started with the first footfall after the 0-foot line and was stopped at the first footfall after the 5 m line. If needed, patients were allowed to use a cane, walker, and/or oxygen support. Patients were asked to walk the timed 5 m distance three times and were given sufficient time for recovery, usually 5-10 s, as needed between walks. If a patient could not walk the 5 m all three times, the single walk time or the average of two walk times was used.
The average time needed to walk the 5 m was used to stratify the patients into fast and slow GS groups, based on their walk speed (s/ 5 m). Gait speed times >6 s have previously been validated by Alfilalo et al to predict increased mortality and major morbidity post cardiac surgery. 11 The fast group in our study completed the walk test in ≤6.0 s The next three components of frailty testing were then evaluated.
Baseline serum albumin was measured and the patient's independence in completing activities of daily living (ADL) was assessed through the completion of the Katz ADL survey. 16 The dominant handgrip strength of each patient was measured in kilograms and collected three times using a dynamometer. Failure was based on sex and body mass index standards. 17 These additional frailty measurements were not collected in all patients based on timing of comprehensive frailty evaluation at the two clinical sites.
Echocardiographic data before and after BAV were collected including peak and mean aortic valve gradient, aortic valve area, and 
| Statistical analysis
Proportions were calculated for categorical variables and means and standard deviations for continuous variables. Chi-square tests were used for comparing across categories for the categorical proportions while analysis of variance was used for the continuous variables.
| 69
Before and after BAV comparisons used paired t tests on patients with before and after data. Kaplan-Meier survival curves were calculated for the first 400 days after BAV. A log-rank calculation tested for differences in the survival curves. All statistical routines used SAS 9.4 software (SAS Inst. Cary N.C.).
The approval of this study was granted by the institutional review board at both centers.
| RESULTS
117 patients were included in this study. pre vs post GS = 0.679) ( Table 2 ). All 19 of the non-ambulatory patients were able to complete GS testing at follow-up, and no patients became non-ambulatory post BAV.
When evaluating other markers of frailty, there was no significant change in hand grip or serum albumin post BAV (Table 2) There was additionally a favorable trend toward decreased BNP at 30 days compared to baseline (800.11 ± 761.30 vs 1470 ± 1217.5,
The number of patients that were referred to definitive valve therapy after BAV was 78/117 (66.7%), comprised of 9/117 (7.7%) to surgical AVR and 69/117 (59.0%) to TAVR.
After BAV, there was a significant increase in aortic valve area Team demonstrated no significant increase overall in mean GS.
However, there was an improvement in all non-ambulatory patients, who were subsequently able to complete GS testing after BAV. A significant improvement in NYHA CHF class in patients after BAV was An analysis of the patients in the PARTNER Trial (Cohort B) who were randomized to medical therapy and subsequently underwent BAV has been reported. 19 Patients who underwent BAV after randomization (n = 102) were compared to patients who did not undergo BAV (n = 38). A short-term (3 month) improvement in survival was seen in the BAV group; with a 6-month improvement in QOL as well as NYHA functional class. While the patients in our study were also high-risk with a mean STS PROM score of 9.6, they were considered "bridge-to-decision" as compared to the patients in the PARTNER trial (where the mean STS PROM score was 11.8). Only 11 of the patients in this arm of the PARTNER trial went on to SAVR, however, this may be secondary to the clinical trial requirements that restricted crossover in the randomized medical therapy arm until the 1-year endpoint had been reached. It is unlikely that BAV can optimize such high-risk patients for this length of time to allow subsequent definitive valve therapy.
There is limited data regarding the outcomes of patients undergoing BAV as a bridge to definitive valve therapy. One Italian study compared 43 patients who underwent BAV prior to TAVR to 40 who did not, and described a significant improvement in NYHA Class III/VI in the BAV group, similar to that seen in our study. 20 Data from the Cleveland Clinic describe the outcomes of 90 patients who underwent BAV in the pre-TAVR era with 27 of the patients improving sufficiently to be referred to SAVR. 21 There was a higher rate of renal dysfunction in patients who were not bridged to surgery compared to those that were, but this was not significant in multivariate analysis. In a study of 423 patients in the UK, 18.3% of the patients who underwent BAV were subsequently referred for TAVR and 7.0% to SAVR, 22 and data from 262 patients undergoing BAV at the Washington Hospital Center from the years 2000 to 2009 reports 10.8% of patients proceeding to SAVR or TAVR. 23 All these studies describe low rates of referral to definitive valve therapy. 24 One singlecenter study in Italy described the outcomes of 202 high-risk patients who underwent BAV as bridge to decision. 25 While the in-hospital mortality was high at 4.5%, of the patients surviving. 75% of the whole group and all 13 of the patients defined as frail by their criteria underwent definitive valve therapy. Our group has recently reported the outcomes of a prospective study describing the outcomes of BAV based on assigned intent of the treating physician: bridge to decision (BTD), bridge to treatment (BTX), or palliation (PAL). 26 Intent in our 100 study patients was 76 BTD; 20 BTX; and 4 PAL. Thirty-day mortality for all patients was 6/100 (6.0%) and 1-year mortality for all patients who received definitive valve therapy was 6/54 (11.1%). For patients surviving to 30 days, adjusted (by STS predicted risk of mortality)
KCCQ scores were significantly improved from baseline for all patients and BTD patients. Thus, as a bridge to decision and treatment tool, BAV appears to have a valuable role in properly selecting and improving patients to undergo definitive valve replacement. While complication rates and mortality rates are reported in each of these studies, changes in clinical features and frailty post BAV are not described, which represent a unique feature of this study.
The evaluation of frailty in our study revealed interesting findings.
While the overall GS did not differ significantly, the ability of all 19 of our non-ambulatory patients to complete GS testing at follow up is a powerful finding. No previously published study has discussed this subset of patients that is unable to complete GS testing at baseline. The finding of improvement in ADL score in patients after BAV demonstrates an additional clinical benefit relevant in deciding candidacy for AVR.
One of the most common reasons to defer referral for valve therapy includes the diagnosis of CHF, with prior reports of BAV describing rates of NYHA CHF Class III/IV over 90%, similar to our data. 19, 21 Our group has reported data demonstrating the improvement in pulmonary function tests after AVR in patients diagnosed with chronic obstructive pulmonary disease (COPD) prior to valve therapy. 27 Thus the shortness of breath in patients with severe AS may be misclassified, such that optimal therapy is not offered. Medical therapy trials of heart failure have focused on an endpoint requiring change in NYHA Class by at least two levels given the granularity of the scale. It is not clear that this is an appropriate goal in the severe AS population, nor whether this can be achieved in the setting of severe symptomatic AS without definitive valve therapy.
In our study, we found an improvement in the patients most symptomatic from a heart failure standpoint; those with NYHA Class IV at baseline. While at baseline approximately 2/3 of patients were
Class IV and 1/3 were Class III, post BAV, approximately 15% were Class IV, 60% Class III, and 30% Class II. This improvement in NYHA Class in our study is similar to that noted in the BAV patients in the PARTNER trial. 19 This was also supported by a trend toward reduction in BNP when comparing baseline to 30 days, such that perhaps this biomarker can be considered as a diagnostic tool post BAV.
The clinical benefits demonstrated in this study of BAV patients must be placed in the context of potential harm of the BAV procedure.
The immediate complication rate of 5.1% in our study, with no procedural deaths, is low and compares favorably to that noted in other BAV studies. 23, 25 This risk balances favorably in this high risk group in which improvement in NYHA CHF and ADL score was seen at one month post procedure. The low rate of complications noted in this study are likely due to a combination of patient selection, improved valve sizing by CT scan, improved procedural technique, and high volume operators performing the procedure. We reported a similarly low rate of complications (4%) in our prospective BAV study. 26 The question remains whether BAV should be recommended for patients with severe symptomatic AS who are not felt to be candidates for TAVR at first evaluation. This study offers useful information regarding improvement in heart failure symptoms and ADL scores. After BAV, certain patients may be improved candidates for definitive valve therapy.
The limitations of this current study include that this is a retrospective, nonrandomized analysis of patients referred for BAV. Thus there may be referral bias on the part of the physicians caring for these patients. Secondly, the exact indication for BAV in this population was not known. Thirdly, the number of patients in this study is small such that the conclusions can be seen as hypothesis-generating and should be confirmed in a larger trial.
Lastly, this study was performed at two high-volume, experienced TAVR centers, such that the results obtained here may not be generalizable to centers earlier in their TAVR experience. Thus the use of BAV in patients being evaluated for TAVR cannot be extrapolated to a widely-adopted strategy, but instead carefully selected based on comprehensive evaluation of individual patient profiles by the heart team.
| CONCLUSION
In this study of high-risk patients evaluated for TAVR, the use of BAV as a bridge-to-decision did not affect the mean GS of all patients, however all non-ambulatory patients were able to perform GS testing at follow-up. There was also improvement in the NYHA CHF class of patients, as well as the ADL score. Due to the improved health status, the majority of patients underwent subsequent valve therapy.
Ongoing research is necessary to develop the appropriate metric for evaluating outcomes post BAV in patients being evaluated for TAVR.
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